VISTA, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (Nasdaq:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Patrick Keran to the newly created position of General Counsel, effective October 12, 2015. Mr. Keran has over 15 years of legal and operational experience, primarily with respect to capital raising, corporate governance and FDA-regulated entities. For the past eight years, Mr. Keran has held progressively senior positions at Mast Therapeutics, a clinical-stage drug development company, most recently as President and Chief Operating Officer, where he oversaw multiple acquisitions and raised close to $250 million.
"I am excited to join the leadership team of SeaSpine and to contribute to the innovation that will drive growth," said Mr. Keran. "I'm looking forward to the opportunity to simplify our operations and approach to the market to make it easier for our surgeon customers and distributors to do business with us."
Mr. Keran will be part of the senior leadership team, reporting directly to Keith Valentine, President and Chief Executive Officer.
"Pat's business experience gives him a practical, solution-oriented mindset that will serve us well as we position ourselves for growth," said Mr. Valentine. "I look forward to Pat's contributions to building a culture of action and accountability, driving our teams to embrace process simplification, and enabling an ethical, compliant path to our future success."
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal fusion hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal fusion hardware product development allows SeaSpine to offer our surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
CONTACT: Investor Relations Contact: Lynn Pieper or Leigh Salvo (415) 513-1281 firstname.lastname@example.org